Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the ligation of PPARγ

Journal of Clinical Investigation

Volumn 112, Issue 6, 2003, Pages 945-955

  Bell Parikh, L Chastine ^a   Ide, Tomomi ^a   Lawson, John A ^a   McNamara, Peter ^a,b   Reilly, Muredach ^a   FitzGerald, Garret A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Phenomix Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 6 OXOPROSTAGLANDIN F1 ALPHA; ALLOPURINOL; CIGLITAZONE; CODEINE; COLCHICINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEUTERIUM; DEXAMETHASONE; ETODOLAC; FOLIC ACID; HYDROXYCHLOROQUINE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INSULIN; ISOBUTYLMETHYLXANTHINE; METHOTREXATE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROSTAGLANDIN E2; SALAZOSULFAPYRIDINE; TRITIUM; UNCLASSIFIED DRUG; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; BIOLOGICAL RESPONSE MODIFIER; CELL RECEPTOR; DRUG DERIVATIVE; ISOENZYME; LIGAND; MEMBRANE PROTEIN; PROSTAGLANDIN D2; PROSTAGLANDIN SYNTHASE; PTGS1 PROTEIN, HUMAN; PTGS1 PROTEIN, MOUSE; PTGS2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADIPOCYTE; ADULT; AGED; ANIMAL CELL; APOPTOSIS; ARTHRITIS; ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GOUT; HUMAN; ISOTOPE LABELING; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; OBESITY; OSTEOARTHRITIS; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; URINARY EXCRETION; ANIMAL; CELL STRAIN 3T3; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SYNOVIAL FLUID; URINE;

3T3 CELLS; ADIPOCYTES; AGED; AGED, 80 AND OVER; ANIMALS; ARTHRITIS; BIOLOGICAL RESPONSE MODIFIERS; CELL DIFFERENTIATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; HUMANS; ISOENZYMES; LIGANDS; MALE; MASS SPECTROMETRY; MEMBRANE PROTEINS; MICE; MIDDLE AGED; PROSTAGLANDIN D2; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SYNOVIAL FLUID; TRANSCRIPTION FACTORS;

EID: 0142186679     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200318012     Document Type: Article

References (62)

1. Lazar, M.A. 2001. Progress in cardiovascular biology: PPAR for the course. Nat. Med. 7:23-24.
2. Rangwala, S.M., and Lazar, M.A. 2000. Transcriptional control of adipogenesis. Annu. Rev. Nutr. 20:535-559.
3. Kersten, S., Desvergne, B., and Wahli, W. 2000. Roles of PPARs in health and disease. Nature. 405:421-424.
4. Rosen, E.D., and Spiegelman, B.M. 2001. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J. Biol. Chem. 276:37731-37734.
5. Narumiya, S., and FitzGerald, G.A. 2001. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest. 108:25-30. doi:10.1172/JCI200113455.
6. Shi, Y., Hon, M., and Evans, R.M. 2002. The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl Acad. Sci. U. S. A. 99:2613-2618.
7. Smith, J.D., et al. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 92:8264-8268.
8. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. 1998. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
9. Hsueh, W.A., and Law, R.E. 2001 PPARγ and atherosclerosis: effects on cell growth and movement. Arterioscler. Thromb. Vasc. Biol. 21:1891-1895.
10. Hoffmann, A., et al. 1993. Purification and chemical characterization of β-trace protein from human cerebrospinal fluid: its identification as prostaglandin D synthase. J. Neurochem. 61:451-456.
11. Jakobsson, P.J., Thoren, S., Morgenstern, R., and Samuelsson, B. 1999. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. U. S. A. 96:7220-7225.
12. 2 in rat brain, spinal cord and pituitary: basal level and regional distribution. Life Sci. 31:2093-2103.
13. 2 into human airways during acute antigen challenge. N. Engl. J. Med 315:800-804.
14. 2. Identification of products formed in vitro. J. Biol. Chem. 258:11713-11718.
15. 2 formed in human plasma. Proc. Natl. Acad. Sci. U. S. A. 81:1317-1321.
16. 2 in nuclei. J. Pharmacol. Exp. Ther. 242:306-311.
17. Narumiya, S., Ohno, K., Fujiwara, M., and Fukushima, M. 1986. Site and mechanism of growth inhibition by prostaglandins. II. Temperature-dependent transfer of a cyclopentenone prostaglandin to nuclei. J. Pharmacol. Exp. Ther. 239:506-511.
18. Straus, D.S., and Glass, C.K. 2001. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 21:185-210.
19. Colville-Nash, P.R., and Gilroy, D.W. 2000. COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation? Prostaglandins Other Lipid Mediat. 62:33-43.
20. 2 metabolite generated during inflammatory processes. J. Biol. Chem. 277:10459-10466.
21. Gilroy, D.W., et al. 1999. Inducible cyclooxygenase may have anti-inflammatory properties. Nat. Med. 5:698-701.
22. Frungieri, M.B., Weidinger, S., Meineke, V., Kohn, F.M., and Mayerhofer, A. 2002. Proliferative action of mast-cell tryptase is mediated by PAR2, COX2, prostaglandins, and PPARγ: possible relevance to human fibrotic disorders. Proc. Natl. Acad. Sci. U. S. A. 99:15072-15077.
23. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97:4844-4849.
24. Rossi, A., et al. 2000. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature. 403:103-108.
25. 2, the peroxisome proliferaror-activated receptor gamma ligand, in urine. Clin. Chem. 47:768-770.
26. 2. Prostaglandins Other Lipid Mediat. 62:15-21.
27. 2 in a normal human male volunteer. J. Biol. Chem. 260:13172-13180.
28. FitzGerald, G.A., Brash, A.R., Falardeau, P., and Oates, J.A. 1981. Estimated rate of prostacyclin secretion into the circulation of normal man. J. Clin. Invest. 68:1272-1275.
29. Patrono, C., et al. 1986. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77:590-594.
30. 2 in a human female with mastocytosis. Prostaglandins. 30:383-400.
31. 2 in human urine. J Biol. Chem. 263:16619-16625.
32. Wright, H.M., et al. 2000. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J. Biol. Chem. 275:1873-1877.
33. Westcott, J.Y., Clay, K.L., and Murphy, R.C. 1985. Preparation of oxygen-18-labeled lipoxygenase metabolites of arachidonic acid. Biomed. Mass Spectrom. 12:714-718.
34. Xue, J.C., Schwarz, E.J., Chawla, A., and Lazar, M.A. 1996. Distinct stages in adipogenesis revealed by retinoid inhibition of differentiation after induction of PPARγ. Mol. Cell Biol. 16:1567-1575.
35. Djian, P., Phillips, M., and Green, H. 1985. The activation of specific gene transcription in the adipose conversion of 3T3 cells. J. Cell Physiol. 124:554-556.
36. Bligh, E.G., and Dyer, W.J. 1959. A rapid method of total lipid excraction and purification. Can. J. Biochem Physiol. 37:911-917.
37. Knott, I., et al. 1993. Routine prostaglandin assay by GC-MS in multi-well tissue culture plates: application to human synoviocytes and chondrocytes. Anal. Biochem. 210:360-365.
38. α2-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. J. Biol. Chem. 273:22442-22452.
39. McAdam, B.F., et al. 2000. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. J. Clin. Invest. 105:1473-1482.
40. 2. Science. 296:539-541.
41. McCloskey, H.M., Rothblat, G.H., and Glick, J.M. 1987. Incubation of acetylated low-density lipoprotein with cholesterol-rich dispersions enhances cholesterol uptake by macrophages. Biochim. Biophys. Acta. 921:320-332.
42. Ueda, S., et al. 1998. Redox regulation of caspase-3(-like) protease activity: regulatory roles of thioredoxin and cytochrome c. J. Immunol. 161:6689-6695.
43. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., and Kliewer, S.A. 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272:3406-3410.
44. Oberfield, J.L., et al. 1999. A peroxisome proliferator-activated receptor γ ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci U. S. A. 96:6102-6106.
45. FitzGerald, G.A., Pedersen, A.K., and Patrono, C. 1983. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation. 67:1174-1177.
46. 2-isoprostanes in human urine. Proc. Natl. Acad. Sci. U. S. A 96:13381-13386.
47. Braden, G.A., Knapp, H.R., and FitzGerald, G.A. 1991. Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. Circulation. 84:679-685.
48. Walczak, R., and Tontonoz, P. 2002. PPARadigms and PPARadoxes: expanding roles for PPAPγ in the control of lipid metabolism. J. Lipid Res. 43:177-186.
49. Davies, S.S., et al. 2001. Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists. J. Biol. Chem. 276:16015-16023.
50. Barry, O.P., Pratico, D., Lawson, J.A., and FitzGerald, G.A. 1997. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J. Clin. Invest. 99:2118-2127.
51. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
52. Chen, Y., Morrow, J.D., and Roberts, L.J., 2nd. 1999. Formation of reactive cyclopentenone compounds in vivo as products of the isoprostane pathway. J. Biol. Chem. 274:10863-10868.
53. Ge, K., et al. 2002. Transcription coactivator TRAP220 is required for PPAR γ2-stimulated adipogenesis. Nature. 417:563-567.
54. 2 with intracellular glutathione and enhancement of its antiproliferative activity by glutathione depletion. Cancer Res. 50:1879-1885.
55. 2. Biochemistry. 29:3760-3765.
56. 2 in vitro and may be an important regulator of PPARγ function in vivo. Endocrinology. 142:551-556.
57. 2, to glutathione. Biochim. Biophys. Acta. 1584:37-45.
58. Fitzgerald, D.J., Roy, L., Cacella, F., and FitzGerald, G.A. 1986. Platelet activation in unstable coronary disease. N. Engl. J. Med. 315:983-989.
59. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J., and Glass, C.K. 1998. The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation. Nature. 391:79-82.
60. 2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IκBα degradation using a peroxisome proliferator-activated receptor γ-independent mechanism. J. Immunol. 168:6232-6243.
61. Anderson, G.D., et al. 1996. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rac adjuvant arthritis. J. Clin. Invest. 97:2672-2679.
62. Bombardieri, S., et al. 1981. The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. Br. J. Pharmacol. 73:893-901.